SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics
(Amex: CXM) today reported financial results and highlights for its third
quarter ended September 30, 2008, and outlined revised business strategies
for its three operating units: (1) InnerCool Therapies, (2) Tissue Repair
Company, and (3) Cardium Biologics.
InnerCool Therapies, Inc.
The Company recently announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market InnerCool's new RapidBlue(TM) endovascular temperature modulation system. This new system automatically cools or warms patients, as necessary, to quickly and controllably achieve and then maintain a desired body temperature. The RapidBlue System provides rapid or gradual temperature control for all patient sizes and is powerful enough to quickly cool awake patients and may eliminate the need to use paralytic agents. During the quarter, the Company also announced CE mark approval and Underwriters Laboratories, Inc. (UL) certification for the RapidBlue which will allow InnerCool to begin marketing the RapidBlue System in Europe and many other countries that recognize these certifications.
InnerCool's CoolBlue(TM) surface temperature modulation system, which
includes a console and a disposable CoolBlue vest with upper thigh pads, is
designed to provide a complementary tool for use in less acute patients or
in clinical settings best suited to prolonged temperature management. The
nurse-friendly and cost-effective CoolBlue System, launched in the U.S. in
fourth quarter 2007, is also now availabl
|SOURCE Cardium Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved